8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

Hermans A, Maris T, Hubert J, Rochas C, Scott K, Murk AJ, Winter HV

Bioeffects Seen

Authors not listed · 2025

Share:

This COVID-19 drug trial was incorrectly categorized as EMF research and contains no electromagnetic field data.

Plain English Summary

Summary written for general audiences

The RECOVERY trial tested two COVID-19 antiviral drugs (molnupiravir and nirmatrelvir-ritonavir) in 1,060 hospitalized patients with COVID-19 pneumonia. Neither drug improved survival rates or reduced hospital stays when added to standard care. Both studies ended early due to low enrollment, making it difficult to rule out potential benefits.

Why This Matters

This study appears to be incorrectly categorized in our EMF Research Hub database - it's actually a clinical trial of COVID-19 antiviral medications with no electromagnetic field component whatsoever. The RECOVERY trial examined pharmaceutical interventions for hospitalized COVID-19 patients, not EMF exposures or their health effects. This highlights an important issue in research databases: proper categorization is crucial for meaningful analysis. When studies are misclassified, it can dilute the quality of evidence synthesis and lead researchers down incorrect paths. For those genuinely interested in EMF health research, this serves as a reminder to carefully verify study relevance and methodology before drawing conclusions about electromagnetic field exposures.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2025). Hermans A, Maris T, Hubert J, Rochas C, Scott K, Murk AJ, Winter HV.
Show BibTeX
@article{hermans_a_maris_t_hubert_j_rochas_c_scott_k_murk_aj_winter_hv_ce4402,
  author = {Unknown},
  title = {Hermans A, Maris T, Hubert J, Rochas C, Scott K, Murk AJ, Winter HV},
  year = {2025},
  doi = {10.1016/s1473-3099(25)00093-3},
  
}
DOI: 10.1016/s1473-3099(25)00093-3PubMed: 40383127

Quick Questions About This Study

This appears to be a database categorization error. The RECOVERY trial studied antiviral medications for COVID-19 patients and contains no electromagnetic field research or EMF exposure data whatsoever.
The trial tested molnupiravir and nirmatrelvir-ritonavir antivirals in 1,060 hospitalized COVID-19 patients. Neither drug improved 28-day survival rates or reduced hospital stays compared to standard care alone.
923 participants were enrolled in the molnupiravir comparison (445 treated, 478 control) and 137 in the nirmatrelvir-ritonavir comparison (68 treated, 69 control). Both studies ended early due to low recruitment.
In the molnupiravir group, 17% died in both treatment and control groups. In the nirmatrelvir-ritonavir group, 19% died in both treatment and control groups within 28 days.
Both antiviral comparisons were stopped due to low patient recruitment. This limited the statistical power to detect meaningful treatment benefits, particularly for the smaller nirmatrelvir-ritonavir study with only 137 participants.